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Serum fatty acid chain length 
associates with prevalent 
symptomatic end‑stage 
osteoarthritis, independent of BMi
J. M. t. A. Meessen1,2,10, f. Saberi‑Hosnijeh3,4,10, n. Bomer2, W. den Hollander2, 
J. G. van der Bom5, J. A. van Hilten5, W. e. van Spil6, c. So‑osman5, A. G. Uitterlinden3, 
M. Kloppenburg7, R. G. H. H. nelissen1, c. M. van Duijn8,9, p. e. Slagboom2,8,11, 
J. B. J. van Meurs3,11 & i. Meulenbelt2,11*
Higher body mass index (BMi) is associated with osteoarthritis (oA) in both weight‑bearing and non‑
weight‑bearing joints, suggesting a link between oA and poor metabolic health beyond mechanical 
loading. This risk may be influenced by systemic factors accompanying BMI. Fluctuations in 
concentrations of metabolites may mark or even contribute to development of oA. this study explores 
the association of metabolites with radiographic knee/hip oA prevalence and progression. A 1H‑nMR‑
metabolomics assay was performed on plasma samples of 1564 cases for prevalent OA and 2,125 
controls collected from the Rotterdam Study, cHecK, GARp/noRRef and LUMc‑arthroplasty cohorts. 
OA prevalence and 5 to 10 year progression was assessed by means of Kellgren-Lawrence (KL) score 
and the OARSI-atlas. End-stage knee/hip OA (TJA) was defined as indication for arthroplasty surgery. 
Controls did not have OA at baseline or follow-up. Principal component analysis of 227 metabolites 
demonstrated 23 factors, of which 19 remained interpretable after quality-control. Associations of 
factor scores with OA definitions were investigated with logistic regression. Fatty acids chain length 
(fALen), which was included in two factors which associated with tJA, was individually associated with 
both overall oA as well as tJA. increased fatty Acid chain Length is associated with oA.
Osteoarthritis (OA) is very prevalent, age-related, progressive degenerative disease of articular joints and one of 
the leading causes of disability and pain  worldwide1. Due to ageing, increased longevity, and increasing obesity 
of the population, the OA incidence is expected to rise even  further2–4. Epidemiological studies have shown that 
unfavourable metabolic parameters, such as high body mass index (BMI), waist-hip ratio and proportion of fat 
mass associated with OA onset and its  severity5–11. Conversely, weight loss has been shown to significantly relief 
pain while increasing physical function of people with knee  OA12–15. Notably, these associations have been found 
for both the weight-bearing joint of the knee and non-weight bearing joints of the hand, suggesting a connection 
between OA and obesity beyond increased  loading16–18. In line with this, OA has been shown to associate with 
classical markers of poor metabolic health such as increased circulating levels of low density lipoprotein (LDL) 
and  cholesterol19,20. However, this connection remains controversial for the hip  joint21.
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Recently, studies investigated metabolic profiles to identify biomarkers of poor metabolic health in association 
with OA and its progression. Few small studies were performed into circulating serum metabolomics biomarkers, 
identifying that ratios of amino acids such as valine and xleucine to histidine and alanine, arginine, aspartate, 
glutamate and proline are associated with  OA22–25. More studies have been performed using synovial fluid which 
have confirmed the some of the aforementioned amino acids, as well as identifying altered energy-, collagen-, 
fatty acid-, glycerolipid-, oxidative stress and nitric oxide-metabolisms26–28 suggesting an altered metabolic state 
of the synovial fluid in OA. However, these hallmarks of the metabolic syndrome (MS) should also be present 
in serum as MS affects not only the synovium but also the whole body. In addition, consensus on biomarkers 
is lacking and the sample size of these studies was generally small. Warranting the need to perform large-scale 
studies to elucidate the link between metabolites and OA.
Therefore, in the current study, we set out to conduct the first large scale metabolomics assessment includ-
ing metabolites ranging from amino acids to lipids to fatty acids in over four thousand cases and controls. We 
aim to identify metabolic signatures of serum by including 2,125 controls and 2,372 OA cases among Dutch 
cohorts participating in the Biobanking and BioMolecular resources Research Infrastructure consortium (BBMRI 
metabolomics consortium)29.
Results
Levels of 231 serum metabolic traits (Supplementary Table 2) were obtained on the NMR (Nightingale) plat-
form. Of the 231 metabolites, 4 [conjugated linoleic acid (CLA), the ratio of CLA to total fatty acids (CLAFA), 
diglycerids (DAG) and ratio DAG to triglycerids (DAG/TG)] had more than 5% of the measurements below the 
detection limit and were excluded from analysis. Analyses of the 227 remaining metabolites was performed in 
2,125 controls and 1,556 OA cases from 4 independent studies participating in the Biobanking and BioMolecu-
lar resources Research Infrastructure consortium (BBMRI metabolomics consortium, Supplementary Table 1). 
Baseline characteristics of cases and controls are shown in Table 1.
principal component analysis (pcA). To reduce data dimensions of the correlated metabolites, PCA 
analyses was performed. In a PCA analysis the underlying the structure of correlation between individual 
metabolites is taken into account and merged into independent factors. As shown in Supplementary Table 3, 23 
factors with an eigenvalue of ≥ 1, accounting for 91,4% of the total variance were identified. Indicating that in the 
227 assessed metabolites, 23 independent correlation structures are present. Prior to the analyses for OA status, 
possible confounding effects of cohorts were investigated by analysing the principal components as function of 
controls of each cohort while adjusting for age, sex, BMI and fasting status. Hereto four factors (factor-2, fac-
tor-10, factor-13 and factor-16), accounting for 28.06% of the variance were removed from the analyses.
cross‑sectional analyses of prevalent overall oA. After adjusting for age, gender BMI and multiple 
testing, we identified five factors (factor-4, factor-11, factor-15 factor-19, and factor-20) that were significantly 
associated to overall OA as defined by a KL score of ≥ 2 or having a total joint arthroplasty in hip and/or knee 
joints (Table 2).
Of these, most significantly associated to overall OA were factor-4 with OR 1.25 95% CI 1.15–1.36, P < 0.001 
and factor 19 OR 0.75, 95% CI 0.69–0.82, P < 0.001. In order to assess the type of biology that each factor repre-
sents, we looked at the individual correlated metabolites for each factor. Based on the metabolites that, among 
others, load on these factors (Supplementary Table 2) we conclude that factor-4 represents mainly the medium 
and large triglycerides to total lipids ratio and factor 19 particularly the amino acids glutamine and histidine). The 
metabolites that represent factor-11 and factor-20 are different types of fatty acid ratios and 3-hydroxybutyrate 
and citrate, respectively. Different cholesterols represent factor-15. Associations separate for hip and knee OA 
were comparable (Supplementary Table 4).
cross‑sectional analyses total joint arthroplasty. To investigate associations among the part of the 
cases representing patients with a total joint arthroplasty surgery, and therefore symptomatic end-stage disease, 
we performed similar cross-sectional analyses with total joint arthroplasty. Even though these analyses had less 
power than the cross-sectional analyses for overall OA due to a smaller sample size, the effect sizes were more 
pronounced and the levels of significance were comparable to the overall OA analyses. After adjusting for age, 
gender, BMI and multiple testing, we identified eight factors (factor-1, factor-4, factor-6, factor-11, factor-17, 
factor-19, factor-22, and factor-23) that were significantly associated to patients with joint arthroplasty of knee 
and/or hip (Table 2).
Table 1.  Baseline characteristics of subjects in the cross-sectional analyses. OA osteoarthritis, TJA Total joint 
arthroplasty. A Overall Radiographic OA as defined by KL-score ≥ 2 and/or total joint arthroplasty.
Controls Overall  OAA TJA
N = 2,125 All N = 1556 Hip N = 736 Knee N = 990 All N = 640 Hip N = 447 Knee N = 199
Female (%) 1,301 (61%) 1,554 (68%) 482 (66%) 700 (71%) 638 (70%) 313 (70%) 142 (72%)
Age (SD) 66.1 (10.1) 70.9 (10.3) 69.6 (11.9) 72.5 (8.6) 68.9 (12.2) 68.0 (13.1) 71.0 (9.3)
BMI (SD) 26.5 (3.9) 28.1 (4.5) 27.5 (4.4) 28.7 (4.5) 28.2 (4.6) 27.6 (4.6) 29.8 (4.1)
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Notably, factor-1, factor-6, factor-17, factor-22, and factor-23 did not show association to overall OA and 
may thus be specifically associated with arthroplasties. These associations were slightly more prominent for 
arthroplasty in the knee as compared to hip arthroplasty (Supplementary Table 5). Based upon the metabolites 
loading on these factors we conclude that factor-1 is mainly representative of the LDL/VLDL metabolism, fac-
tor -6 represents cholesterol(esters), factor-17 and factor-23 represent different aspects of the energy cycle and 
factor-22 represents fatty acid make-up.
To further assess the confounding effect of fasting-status, we performed additional analyses in- and exclud-
ing adjustment for fasting. As shown in Supplementary Table 6, the association of the factors with OA remained 
consistent with and without an adjustment for fasting. Also, upon splitting the cohort in those with BMI < 30 and 
BMI ≥ 30, most factors showed similar odds ratio’s between the two groups. Notably, the effect of factor 4 and 17 
was slightly larger in the more obese group while factor 19 was stronger in those with BMI < 30. Factor 22 was 
the most robust with comparable Odds Ratio’s between the two groups (Supplementary Table 7).
cross‑sectional analyses of individual metabolites. Factors 1, 4, 6, 11, 17, 19, 22 and 23, which were 
associated with arthroplasty, were selected for further in-depth analysis. To investigate whether any of the indi-
vidual metabolites within the identified factors drive the associations, we assessed the association with the indi-
vidual metabolites significantly represented in these factors (loading on the factor > 0.4 or < − 0.4). As shown 
in Supplementary Table 8, the majority of the individual metabolites in the factors were associated to a similar 
extent (OR and P-value) to arthroplasty and as such reflect high correlation between the individual metabolite 
features within a factor. A notable exception, however, is FALen (Fatty Acid chain Length) represented in fac-
tor-1 and factor-22. The association with the individual FALen metabolite stands out as it appears to give the 
strongest and most specific association with TJA (OR 1.83, 95% CI 1.64–2.05, P < 0.001, see also Table 3. In 
order to assess any differences in the association of FALen and joint site, we have assessed the association of 
FALen with different joint sites and phenotypes. As shown in Table 3, FALen was significantly associated with 
all included phenotypes, with the strongest association found for knee arthroplasty. Additionally, as shown in 
Supplementary Table 7, factor 22 driven by FALen is stable across the different BMI strata. As statins might affect 
the concentrations of metabolites, we performed sensitivity analyses to assess their influence on our outcomes. 
The use of statins was known for all included studies except CHECK. Sensitivity analysis revealed only minor 
changes in the effect sizes. Similarly, upon in- and excluding an adjustment for statins in the analyses, the Odds 
Ratio’s changed marginally.
progression of oA. As FALen showed strong associations with TJA as well as with overall OA (OR 1.26, 
95% CI 1.16–1.36, P < 0.001), we next explored its association with the progression of OA. Progression data was 
available for N = 2009 (N = 721 non-progressors and N = 305 progressors in the Rotterdam Study and N = 522 
non-progressors and N = 130 progressors in CHECK) (Materials and Methods). As shown in (Supplementary 
Table 2.  Cross-sectional analyses of factors with prevalent overall osteoarthritis and total joint arthroplasty. 
OA osteoarthritis, TJA Total joint arthroplasty, OR Odds Ratio, 95%CI 95% Confidence interval. A Overall 
Radiographic OA as defined by KL-score ≥ 2 and/or total joint arthroplasty. BAdjusted for age, gender, BMI and 
multiple testing.
Factor Controls
Overall  OAA (N = 1556) TJA (N = 640)
OR 95%CI PadjustedB OR 95%CI PadjustedB
1 2,125 0.96 0.88–1.04 NS 0.79 0.70–0.89 2.6 × 10–3
3 2,125 0.98 0.90–1.07 NS 1.10 0.96–1.25 NS
4 2,125 1.25 1.15–1.36 3.0 × 10–6 1.44 1.26–1.64 1.2 × 10–6
5 2,125 1.01 0.93–1.09 NS 0.99 0.86–1.13 NS
6 2,125 1.04 0.96–1.13 NS 1.20 1.07–1.34 4.5 × 10–2
7 2,125 0.91 0.85–0.99 NS 0.84 0.74–0.95 NS
8 2,125 1.03 0.94–1.12 NS 1.12 0.96–1.30 NS
9 2,125 1.03 0.94–1.11 NS 0.93 0.82–1.06 NS
11 2,125 0.87 0.80–0.93 4.3 × 10–3 0.78 0.69–0.88 1.7 × 10–3
12 2,125 1.00 0.92–1.08 NS 1.05 0.93–1.19 NS
14 2,125 1.02 0.94–1.10 NS 1.04 0.92–1.18 NS
15 2,125 0.84 0.77–0.91 3.4 × 10–4 0.86 0.75–0.97 NS
17 2,125 1.02 0.95–1.11 NS 1.36 1.21–1.54 1.2 × 10–5
18 2,125 0.89 0.82–0.96 NS 0.90 0.79–1.04 NS
19 2,125 0.75 0.69–0.82 7.6 × 10–9 0.64 0.56–0.74 9.6 × 10–9
20 2,125 0.85 0.78–0.93 5.0 × 10–3 0.91 0.79–1.04 NS
21 2,125 0.93 0.86–1.01 NS 0.99 0.87–1.13 NS
22 2,125 1.12 1.04–1.21 NS 1.50 1.33–1.7 2.2 × 10–9
23 2,125 1.03 0.95–1.11 NS 1.51 1.33–1.72 9.0 × 10–9
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Fig. 1) and despite the high and consistent cross sectional association the individual metabolite FALen was not 
associated to OA progression.
Discussion
Serum metabolomic assays of hip and knee OA cases and controls were assessed by means of the Nightingale 1H-
NMR platform, resulting in 227 different metabolite measurements. PCA-analysis identified 23 factors explain-
ing 71.9% of variance, of which 19 were eligible for further regression analyses. Eight factors (factor-1, factor-4, 
factor-6, factor-11, factor-17, factor-19, factor-22 and factor-23) were associated with total joint arthroplasty 
independent of age, sex and BMI. Assessing the association of individual metabolites of these factors with 
TJA revealed a highly significant association between Fatty Acid Chain Length (FALen) and Any OA or TJA 
(P < 0.001). Upon splitting the phenotypes by joint site (hip or knee) consistent, significant positive association 
was found for FALen and all four additional phenotypes. As such, this study places a composite score of fatty 
acid length at the heart of the link of osteoarthritis and metabolites. This study showed that FALen has a strong 
association with end stage OA as represented by overall radiographic OA (OR 1.26) but particularly to joint 
arthroplasty (OR 1.83).
Recently, the comprehensive review by Harasymowicz et al. described the many ways how fatty acids influence 
not only the cartilage, but also bone and synovial fluids in the  joint30. Specifically, they describe that longer chain 
saturated fatty acids have a negative impact on the homeostasis of cartilage and chondrocyte metabolism. In 
addition, long-chain SFA inhibits osteoclast-genesis, whereas shorter-chain SFA enhance osteoclast-genesis30,31. 
Another recent study has shown that longer-chain dietary fatty acids in rats induce both metabolic syndrome 
and changes in the knee joint resembling  OA32, all confirming our finding that longer chains of the fatty acid are 
associated with end stage, symptomatic OA. Fatty acids are known to play a role in a broad range of cardiovascu-
lar diseases as well as to the immune system, which might hint that there is a more generic pathway underlying 
the association of OA and fatty acid make  up33,34. This finding was supported by the study of Senol et al. in OA 
patients which demonstrated that there are differences in the metabolic pathways of fatty acid biosynthesis path-
ways between OA patients and  controls35. Given these studies, we advocate that the length of the Fatty Acid Chain 
is underlying the risk of OA susceptibility by directly affecting chondrocyte energy metabolism. Indeed, pathways 
which are activated during high concentrations of fatty acid in blood such as mTOR and AMPK are found to 
be associated with knee OA in mouse. Leading to increased apoptosis in mouse knee and aging of the murine 
 cartilage36. Reduced AMPK is associated with a loss of mitochondrial function, which in turn leads to ageing of 
the  cartilage37. Again, this indicates a more generic pathway underlying the association of fatty acids with  OA38.
We did not demonstrate any association of FALen with OA progression. This may be explained by the fact 
that OA progression was defined by KL-scores alone, as such differ as the symptomatic end stage OA of patients 
undergoing arthroplasty. For that matter, in Supplementary Fig. 1 it is suggested that the effect for FALen and 
OA-progression is larger in the CHECK cohort as compared to that in the Rotterdam study as inclusion criteria 
of CHECK patients were based on symptoms and in the Rotterdam Study based on radiographic OA alone.
FALen was present in both Factor-1 and Factor-22, the first explaining a large part of the variance in data 
(31.25%), whereas factor-22 explains 0.49%. The fact that FALen is present in both and that both are significantly 
associated with TJA, shows that it is worthwhile to explore also small factors. Notably, two other metabolites 
that were represented in factor-22, hence showing an underlying correlation structure to FALen, were Degree of 
Unsaturation (UnsatDeg) and ratio of saturated fatty acids (SFA FA). Nonetheless, the absence of association of 
these metabolites to TJA (Supplementary Table 8) confirms that the found association of Factor-22 to TJA (OR 
1.50, 1.33–1.70) is almost totally attributional to fatty acid chain length (FALen; OR 1.83, 1.64–2.05) and not to 
fatty acid saturation (UnsatDeg OR 1.12, 95% CI 0.99–1.28 and SFA FA OR 0.95 95% CI 0.84–1.07).
The fact that FALen is also present in Factor-1, alongside many other metabolites in the LDL/VLDL range, 
shows that besides its own specific interaction with OA, FALen plays a role through lipid-transportation, as is 
reflected by Factor-130. This double presence shows the highly correlated interplay of metabolites and reflects 
the fact that the length of a fatty acid chain length alters the characteristics of the fatty acid, influencing the 
metabolism. Although studies have shown that the link between OA and obesity is more often present in knee 
OA, we found in this study that FALen is associated to both knee and hip OA, with the strongest association 
found for knee replacement surgery. This may indicate a more general link between OA and fatty acid length, 
Table 3.  Cross sectional analyses of metabolite FALen representing fatty acid chain length with different OA 
types. FALen fatty acid chain length, THA total hip arthroplasty, TKA total knee arthroplasty. A Adjusted for 
age, gender, BMI and multiple testing.
Phenotype Ncontrols Ncases
FALen
OR 95% CIL PadjustedA
All OA 2,125 1556 1.26 1.16–1.36 3.6 × 10–8
Hip OA 2,125 736 1.39 1.26–1.54 8.2 × 10–10
Knee OA 2,125 990 1.15 1.05–1.25 2.1 × 10–2
Arthroplasty 2,125 640 1.83 1.64–2.05 1.0 × 10–320
THA 2,125 447 1.73 1.52–1.98 3.2 × 10–15
TKA 2,125 199 2.10 1.75–2.51 5.6 × 10–15
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beyond obesity and knee OA which is also supported by the stable associations of factor 22 (driven by FALen) 
across the BMI strata (Supplementary Table 7).
In this study, we choose to differentiate between patients who underwent total hip or knee arthroplasty from 
patients with radiographic signs of OA. This because arthroplasty-patients are essentially in a different (end)stage 
of the disease, and an additional incentive to undergo joint replacement surgery has taken place. In contrast, 
patients with radiological OA represent a range of patients with symptoms who may not (yet) be severe enough 
for an indication for arthroplasty. The fact that we observed stronger associations with arthroplasty patients, in 
spite of lower power, supports the view that deviation of metabolic profiles gradually accompanies aspects of 
the OA process towards a joint replacement surgery. However, disentangling the relationship between FALen, 
OA symptoms, and joint replacement requires additional in depth investigation preferably in studies in which 
symptoms, radiographic OA and the incentive towards a joint replacement surgery is accurately documented.
A strength of our study was the relatively large sample size as compared to reported studies. The combina-
tion of different studies to reach more power also meant that we incorporated some studies with only cases or 
controls, raising the chance of cohort effects. However, we did assess the presence of cohort effects within the 
control group, where no differences should be present between the cohorts as all samples are OA-free. Only fac-
tors free of cohort effects were included in our analyses. We adjusted our analyses for baseline-BMI; however, we 
cannot exclude bias in our findings due to the effect of weight loss or gain during follow-up. Our study included 
both fasted and nonfasted samples while metabolites may be sensitive to fasting status, therefore we assessed the 
influence of including a correction or fasting status to assess dietary influences. Despite the fact that food intake 
influences metabolite patterns the association with OA remained  untouched39. We demonstrated only marginal 
changes, i.e. effect sizes were very similar.
The current paper is to our knowledge the first large scale hypothesis free approach in search for metabolites 
that associate to OA in a cross-sectional design. Future research should particularly focus on replication of the 
found results and, if this succeeds, further elucidate the mechanisms behind the association of fatty acid chain 
length and OA.
In conclusion, the current study identified a number of metabolic factors associated with OA, independent of 
BMI. This indicates that there is an altered metabolic state in patients with OA as compared to controls without 
OA. This is another token that OA should be seen as a component of poor metabolic health and that recording 
systemic factors of health status in older people may represent an informative marker of OA risk.
Methods
Study populations. Metabolic signatures were assessed in N = 2,125 controls and N = 1,556 cases from 
4 Dutch cohorts being Cohort Hip & Cohort Knee (CHECK, N = 864), Genetics, Arthrosis and Progression 
(GARP-study, N = 216) with its NORmal REFerence Controls (NORREF, N = 34), Leiden University Medical 
Centre (LUMC) Arthroplasty studies (LUMC-cohorts N = 455) and the Rotterdam study (N = 2,112) that par-
ticipated in the Biobanking and BioMolecular resources Research Infrastructure consortium (BBMRI metab-
olomics consortium)29. Distribution of cases and controls across these studies is depicted in Supplementary 
Table 1. Informed consent was obtained from all included participants. The experiment protocol was followed 
according to the Declaration of Helsinki and good clinical practice. In addition, this study was assessed by 
the steering committees of each included study and the Medical Ethics Committees of all participating centres 
approved the study [Albert Schweitzer Hospital (Dordrecht), Atrium Medisch Centrum (Heerlen), Canisius-
Wilhelmina Ziekenhuis (Nijmegen), Erasmus Medical Center (Rotterdam), Groene Hart Hospital (Gouda), 
Isala Klinieken (Zwolle), Kennemer Gasthuis (Haarlem), Leyenburg ziekenhuis (The Hague) Leids Universitair 
Medisch Centrum (Leiden), Maastricht University Medical Center (Maastricht), Martini Ziekenhuis (Gronin-
gen), Medisch Centrum Alkmaar (Alkmaar), Medisch Centrum Haaglanden (The Hague), Medisch Spectrum 
Twente (Enschede), Reade (Amsterdam), Reinier de Graaf Groep (Delft), Rijnland ziekenhuis (Leiderdorp), Slo-
tervaart Hospital (Amsterdam), St. Antonius ziekenhuis (Nieuwegein), St. Joseph Ziekenhuis (Veldhoven), St. 
Maarten’s Gasthuis (Venlo) Tweesteden Ziekenhuis (Tilburg), Universitair Medisch Centrum Utrecht (Utrecht), 
Ziekenhuis Rijnstate (Arnhem)].
CHECK is a prospective, 10-year follow-up, observational cohort study of 1,002 people aged between 45 
and 65 years at the time of inclusion, with pain in their knee(s) and/or hip(s), who had never or not longer than 
6 months ago visited a general physician for these  complaints40. Blood samples were taken non-fasted. Hip and 
knee radiographs were scored pairwise according to the Kellgren & Lawrence (KL) scoring  system41. When 
scored pairwise, these people did not have obvious radiographic knee or hip OA at baseline (i.e. KL = 0 or 1). As 
such, these persons were considered controls for the cross-sectional analyses on OA prevalence at baseline. For 
the current study we included 864 persons from the CHECK Cohort.
GARP/NORREF study: The GARP cohort (N = 216) consists of patients with advanced radiographic OA 
at two or more joint sites of hand, spine, knee or hip. Matched to the GARP study, a normal reference control 
group (NORREF) was collected using the same protocol and included in this study as controls (N = 34)42–44. In 
the current study baseline non-fasting plasma samples were included.
LUMC cohorts: The LUMC arthroplasty studies (N = 455) consist of participants of the “Research Arthritis 
and Articular Cartilage” (RAAK), “Transfusion induced complications = Transfusion associated complications?” 
(Tactics) (NTR309) and “Transfusie op Maat” (TOMaat) (NTR303)  studies45,46. These cross-sectional studies 
included OA patients who received THA or TKA. Blood samples were collected during surgery while patients 
were fasted.
Rotterdam Study: The Rotterdam Study (RS) is a large prospective population-based cohort study of men 
and women aged 55 years and older in the municipality of Rotterdam, the Netherlands. The study design and 
rationale are described elsewhere in  detail47. In summary, the objective of the study is to investigate determinants, 
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incidence and progression of chronic disabling diseases in the elderly. Baseline measurements were obtained 
through a home interview and visits to the research centre for physical examinations and imaging and labora-
tory assessments, blood samples were taken while patient was fasted. The present study includes 2,112 baseline 
participants from RS-I (Ergo 4). The study included both individuals with and without OA with a mean follow-
up time of 6.5 year. Blood was sampled nonfasted. The study included both individuals with and without OA at 
baseline with mean follow-up time of 6.5 years.
Definitions of OA. Prevalent radiographic OA was (N = 1556) defined as either having a KL score of ≥ 2 in 
hip and/or knee at baseline or having THA or TKA for primary  OA41. THA/TKA patients (N = 640) were also 
assessed separately. Controls (N = 2,125) had no radiographic hip and knee OA (KL < 2) and were selected from 
the Rotterdam Study, CHECK and NORREF as described above. Controls were selected from CHECK and the 
Rotterdam Study and had no radiographic signs of OA in knee or hip. Data on radiographic OA progression 
were available for CHECK (10 year FU), and the Rotterdam Study (6.5 year FU). Progression was defined as 
any increase in KL score, resulting in a KL score of ≥ 2 at follow-up. Thus, both incidence (KL score of 0 or 1 
at baseline and ≥ 2 at follow-up) and progression (increase at KL score with a baseline of ≥ 2) were defined as 
progression in our analyses.
Metabolite measurement. EDTA plasma samples were shipped to Nightingale to perform standardized 
metabolomics analyses on a high throughput platform (Nightingale Ltd, Helsinki, Finland). The 1H-NMR tech-
nique used by Nightingale provides simultaneous quantification of routine lipids, lipoprotein subclass profiling 
with lipid concentration units, resulting in 231 measurements. Details of the techniques have been described 
 before48,49.
Statistical analyses. Metabolites with more than 5% below detection limit were removed from analysis. 
Principal component analysis (PCA) was applied to reduce the data dimension of correlated metabolites. PCA 
groups variables (metabolites) into factors in order to explain variance present in the data. Factors with an eigen-
value above 1 after Varimax rotation with Kaiser Normalization were included in analyses. A metabolite was said 
to load on a given factor if its factor loading was > 0.4 or < − 0.4. For each subject, a score was computed for the 
measures loaded on the factor, representing the linear relationship (Pearson correlation under Varimax rotation) 
between a factor and variable.
The remaining factors were included in logistic regression analyses to assess their association with OA, 
adjusting for age, sex and BMI and multiple testing. As it is hard to interpret the overall meaning of a factor, the 
individual metabolites of factors with significant associations to both OA and TJA were included in individual 
logistic regression analyses after LN-transformation and Z-standardization. All P-values were adjusted accord-
ing to Bonferroni.
Since follow-up was performed at different time points, the progression analyses were done by means of 
meta-analysis. The summary statistics (regression coefficients and standard errors) of CHECK were combined 
with the summary statistics of the Rotterdam Study in a random effects meta-analysis. To assess the modifying 
role of fasting, analyses were also performed without an adjustment. Analyses were performed by means of IBM 
SPSS Statistics version 24 and the “meta-package” of R.
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